Winrevair (sotatercept-csrk) - BMS, Merck (MSD)
Sotatercept Improves Right Heart Mechanics Despite Reduced Myocardial Contractility in Pulmonary Arterial Hypertension: A Prospective Exercise Hemodynamic Study. (PubMed, Circulation) - Sep 23, 2026 - P4 | "These data suggest that sotatercept causes an energetically favorable reduction in resting RV contractility to match the lower afterload, which does not appear physiologically detrimental when considering the concurrent improvement in RV free wall contractile mechanics and exertional right heart reserve. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06409026." 
Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42770225
 
Barry A Borlaug; Daniel Burkhoff; Robert P Frantz; Sho Kazui; Tomonari Harada; William R Miranda; Yogesh N V Reddy
 
Sep 23, 2026
 
Prev Next